Testing for Hereditary Breast Cancer: Panel or Targeted Testing? Experience from a Clinical Cancer Genetics Practice

Journal of Genetic Counseling

Volumn 24, Issue 4, 2015, Pages 683-687

  Doherty, Jennifer ^a   Bonadies, Danielle C ^a   Matloff, Ellen T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA; Breast cancer; Genetic testing; Panel testing

Indexed keywords

BRAP PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ADULT; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIATION; GENETICS; HUMAN; MALE; PROCEDURES; RETROSPECTIVE STUDY;

ADULT; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; HUMANS; MALE; RETROSPECTIVE STUDIES; UBIQUITIN-PROTEIN LIGASES;

EID: 84938213446     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-014-9796-2     Document Type: Article

References (22)

1. Ambry Genetics. (2014). BRCAplus: A 6-gene hereditary breast cancer test. White Paper. http://www.ambrygen.com/sites/default/files/pdfs/forms/most_updated/cancer/BRCAPlus_While %20_Paper_0214.pdf. Accessed on June 11, 2014.
2. Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., & Easton, D. F. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics, 72(5), 1117–1130. doi:10.1086/375033.
3. Arpino, G., Bardou, V. J., Clark, G. M., & Elledge, R. M. (2004). Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Research, 6(3), R149–R156. doi:10.1186/bcr767.
4. Association for Molecular Pathology v. Myriad Genetics, Inc., et al. (2013). 12–398.
5. Benusiglio, P. R., Malka, D., Rouleau, E., De Pauw, A., Buecher, B., Nogues, C., & Caron, O. (2013). CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. Journal of Medical Genetics, 50(7), 486–489. doi:10.1136/jmedgenet-2012-101472.
6. Chen, W.Y., & Colditz, G.A. (2006). Patient information: Tamoxifen and raloxifene for the prevention of breast cancer. 14.2:7.
7. Chompret, A., Brugieres, L., Ronsin, M., Gardes, M., Dessarps-Freichey, F., Abel, A., & Feunteun, J. (2000). P53 germline mutations in childhood cancers and cancer risk for carrier individuals. British Journal of Cancer, 82(12), 1932–1937. doi:10.1054/bjoc.2000.1167.
8. Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., & National Comprehensive Cancer, N. (2010). Genetic/familial high-risk assessment: breast and ovarian. Journal of the National Comprehensive Cancer Network, 8(5), 562–594.
9. Daly, M., Axilbund, J., Buys, S., & Crawford, B. (2014). Genetics/familial high-risk assessment: Breast and Ovarian, Version 1.2014: National Comprehensive Cancer Network, Inc.
10. Fitzgerald, R. C., Hardwick, R., Huntsman, D., Carneiro, F., Guilford, P., Blair, V., & International Gastric Cancer Linkage, C. (2010). Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Journal of Medical Genetics, 47(7), 436–444. doi:10.1136/jmg.2009.074237.
11. Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., & Weitzel, J. N. (2009). Beyond li fraumeni syndrome: clinical characteristics of families with p53 germline mutations. Journal of Clinical Oncology, 27(8), 1250–1256. doi:10.1200/JCO.2008.16.6959.
12. Hearle, N., Schumacher, V., Menko, F. H., Olschwang, S., Boardman, L. A., Gille, J. J., & Houlston, R. S. (2006). Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clinical Cancer Research, 12(10), 3209–3215. doi:10.1158/1078-0432.CCR-06-0083.
13. Hilbers, F. S. M., Vreeswijk, M. P. G., van Asperen, C. J., & Devilee, P. (2013). The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation? Clinical Genetics, 84(5), 407–414. doi:10.1111/Cge.12256.
14. Howlander, N. (2011). SEER cancer statistics review, 1975–2010. Bethesda: National Cancer Institute.
15. Kurian, A., Brugieres, L., Ronsin, M., Gardes, M., Dessarps-Freichey, F., Abel, A., Feunteun, J. (2014). Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. Epub ahead of print.
16. Masciari, S., Van den Abbeele, A. D., Diller, L. R., Rastarhuyeva, I., Yap, J., Schneider, K., & Garber, J. E. (2008). F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA, 299(11), 1315–1319. doi:10.1001/jama.299.11.1315.
17. Mauer, C. B., Pirzadeh-Miller, S. M., Robinson, L. D., & Euhus, D. M. (2014). The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genetics in Medicine, 16(5), 407–412.
18. Nelson, H.D., Fu, R., Griffin, J.C., Nygren, P., Smith, M.E., & Humphrey, L. (2009). Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med, 151(10), 703–715, W-226-735. doi: 10.7326/0003-4819-151-10-200911170-00147.
19. Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., Offit, K., & American Society of Clinical, O. (2010). American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893–901. doi:10.1200/JCO.2009.27.0660.
20. Salmon, A., Amikam, D., Sodha, N., Davidson, S., Basel-Vanagaite, L., Eeles, R. A., & Peretz, T. (2007). Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline ‘de-novo’ TP53 mutation. Clinical Oncology (Royal College of Radiologists), 19(7), 490–493. doi:10.1016/j.clon.2007.05.001.
21. Schrader, K. A., Masciari, S., Boyd, N., Wiyrick, S., Kaurah, P., Senz, J., & Huntsman, D. G. (2008). Hereditary diffuse gastric cancer: association with lobular breast cancer. Familial Cancer, 7(1), 73–82. doi:10.1007/s10689-007-9172-6.
22. Tan, M. H., Mester, J. L., Ngeow, J., Rybicki, L. A., Orloff, M. S., & Eng, C. (2012). Lifetime cancer risks in individuals with germline PTEN mutations. Clinical Cancer Research, 18(2), 400–407. doi:10.1158/1078-0432.CCR-11-2283.